- Home
- SGMT vs MOLN Comparison
SGMT vs MOLN Comparison
Compare SGMT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SGMT | MOLN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 154.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGMT | MOLN |
|---|---|---|
| Price | $8.98 | $4.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $26.13 | $8.38 |
| AVG Volume (30 Days) | ★ 1.0M | 1.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $3.46 |
| 52 Week High | $10.06 | $5.36 |
Technical Indicators
Market Signals| Indicator | SGMT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 52.06 |
| Support Level | $6.95 | $3.94 |
| Resistance Level | $8.84 | $4.13 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 90.51 | 62.28 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.